These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 17335844

  • 1. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.
    J Immunol Methods; 2007 Apr 10; 321(1-2):19-31. PubMed ID: 17335844
    [Abstract] [Full Text] [Related]

  • 2. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
    McKay F, Schibeci S, Heard R, Stewart G, Booth D.
    J Immunol Methods; 2006 Mar 20; 310(1-2):20-9. PubMed ID: 16448664
    [Abstract] [Full Text] [Related]

  • 3. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
    Massart C, Gibassier J, Oger J, Le Page E, Edan G.
    Clin Chim Acta; 2007 Feb 20; 377(1-2):185-91. PubMed ID: 17123498
    [Abstract] [Full Text] [Related]

  • 4. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Deisenhammer F, Schellekens H, Bertolotto A.
    J Neurol; 2004 Jun 20; 251 Suppl 2():II31-9. PubMed ID: 15264110
    [Abstract] [Full Text] [Related]

  • 5. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
    Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J.
    J Immunol Methods; 2008 Jul 31; 336(2):113-8. PubMed ID: 18511063
    [Abstract] [Full Text] [Related]

  • 6. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G.
    Mult Scler; 2011 Nov 31; 17(11):1333-40. PubMed ID: 21685230
    [Abstract] [Full Text] [Related]

  • 7. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C, Gibassier J, de Seze J, Debouverie M, Moreau T, Pelletier J, Vermersch P, Edan G.
    Clin Chim Acta; 2008 May 31; 391(1-2):98-101. PubMed ID: 18249193
    [Abstract] [Full Text] [Related]

  • 8. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
    Millonig A, Rudzki D, Hölzl M, Ehling R, Gneiss C, Künz B, Berger T, Reindl M, Deisenhammer F.
    Mult Scler; 2009 Aug 31; 15(8):977-83. PubMed ID: 19465447
    [Abstract] [Full Text] [Related]

  • 9. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D, Sellebjerg F, Sorensen PS.
    Neurology; 2009 Aug 04; 73(5):372-7. PubMed ID: 19652141
    [Abstract] [Full Text] [Related]

  • 10. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
    Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A.
    Mult Scler; 2007 Mar 04; 13(2):208-14. PubMed ID: 17439886
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera.
    Gilli F, van Beers M, Marnetto F, Jiskoot W, Bertolotto A, Schellekens H.
    J Immunol Methods; 2008 Jul 31; 336(2):119-26. PubMed ID: 18558408
    [Abstract] [Full Text] [Related]

  • 18. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.
    Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A, Capobianco M, Bertolotto A.
    J Neuroimmunol; 2005 Jan 31; 158(1-2):195-203. PubMed ID: 15589054
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF, Kok A, Visser A, Oudejans CB, Caldano M, Gilli F, Bertolotto A, Polman CH, Killestein J.
    Mult Scler; 2009 Feb 31; 15(2):212-8. PubMed ID: 18805837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.